Three series of novel imidazoline derivatives were designed, synthesized, and evaluated for their p53–MDM2 binding inhibitory activities, and anti-proliferation activities against PC3, A549, KB, and HCT116 cancer cell lines. Five of the tested compounds showed enhanced p53–MDM2 binding inhibitory potency and anti-proliferation activities in comparison with that of Nutlin-1. Flow cytometric analysis indicated that compound 7c, one of the most ...
[Van Veldhuizen, Joshua J.; Gillingham, Dennis G.; Garber, Steven B.; Kataoka, Osamu; Hoveyda, Amir H. Journal of the American Chemical Society, 2003 , vol. 125, # 41 p. 12502 - 12508]